This is a working overview of cyclic heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or flake |
| Solubility class | Soluble in water and aqueous buffer | Also soluble in some polar organic solvents |
| Typical storage temperature | Minus 20 degrees Celsius or below | Desiccated and protected from light |
| Typical analytical method | LC-MS/MS | Reversed-phase separation with mass detection |
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
The reactions that follow the formation of FKA consist of the aromatization and functionalization stages. FKA is subjected to two rounds of hydroxylation catalyzed by two distinct P450 monooxygenases forming flavokermesic acid and kermesic acid, respectively. Whether these monooxygenases are oxygen or flavin dependent is to be determined. The first monooxygenation occurs in the central aromatic ring carbon, C10 while the second occurs in the C4 position. The final attachment of a carbohydrate onto the C2 position C-glycosylation reaction is catalyzed by a UDP-glucose dependent membrane bound glucosyltransferase. The order of the last two steps has not been determined due to lack of experimental kinetic data.
Within the United States, the impacts generally observed during the six-month period include wetter-than-average conditions along the Gulf Coast between Texas and Florida, while drier conditions are observed in Hawaii, the Ohio Valley, Pacific Northwest and the Rocky Mountains. Study of more recent weather events over California and the southwestern United States indicate that there is a variable relationship between El Niño and above-average precipitation, as it strongly depends on the strength of the El Niño event and other factors. Though it has been historically associated with high rainfall in California, the effects of El Niño depend more strongly on the "flavor" of El Niño than its presence or absence, as only "persistent El Niño" events lead to consistently high rainfall. To the north across Alaska, La Niña events lead to drier than normal conditions, while El Niño events do not have a correlation towards dry or wet conditions. During El Niño events, increased precipitation is expected in California due to a more southerly, zonal, storm track. During La Niña, increased precipitation is diverted into the Pacific Northwest due to a more northerly storm track. During La Niña events, the storm track shifts far enough northward to bring wetter than normal winter conditions (in the form of increased snowfall) to the Midwestern states, as well as hot and dry summers. During the El Niño portion of ENSO, increased precipitation falls along the Gulf coast and Southeast due to a stronger than normal, and more southerly, polar jet stream.
=== The 53Mn – 53Cr chronometer === The short-lived 53Mn-53Cr chronometer is based on the radioactive decay of 53Mn to 53Cr with a half-life of 3.80 ± 0.23 million years. Because manganese and chromium are moderately volatile elements, their fractionation in the cooling solar nebula makes this chronometer particularly suited for dating volatile element depletion events in early Solar System materials. The initial homogeneous distribution of 53Mn in the Solar System, a prerequisite for its use as a chronometer, was established in early studies of Solar System materials. Applied to meteorites, 53Mn-53Cr systematics have provided key insights into the origin of chondrite parent bodies and the volatile element depletion history of the early Earth. The volatile element depletion of proto-Earth was established no later than ~3 million years after the formation of calcium-aluminium-rich inclusions (CAIs), contemporaneous with the dissipation of the protoplanetary disk, while full planetary accretion was completed within ~70 million years.
According to Joseph Bernstein of The New York Times, Peters was earning more than $100,000 a month by February 2026 from his Kick livestreams. Peters revealed during a March 2026 livestream that he earned over $100,000 a month from Kick livestreams. However in August 2026 Peters stated that he would move away from Kick and their owner Stake Online Casino after being sponsored by Duel Casino. Peters has appeared as a blackjack dealer for Duel, for which he was officially signed as the "main character of Duel.com's second season." In an interview conducted with Adam Hegarty for 60 Minutes Australia in April 2026, Hegarty asked Peters if he was an incel due to his associations with "looksmaxxing" (a term initially coined by the incel community) and with Andrew Tate; Peters replied that "looksmaxxing" had nothing to do with incel culture, and abruptly ended the interview. Questioned by Sean Hannity on his sexual status, for the July 21, 2026, episode of Hang Out with Sean Hannity, Peters said: "People will often try to associate looksmaxxing with incel culture and being super resentful of women, when it's actually the antithesis of that, right? Looksmaxxing is trying to escape inceldom, if anything, so for that link to try to be made makes no sense to me whatsoever." Peters announced a national "college partytype tour" which included his arrival at Texas A&M University on August 28, 2026. A nightclub that had arranged for his Clemson University stop cancelled his event scheduled for August 26, 2026, citing safety concerns for guests and staff.
Sources: en.wikipedia.org
=== Blood sugar and insulin levels === Erythritol has no effect on blood sugar or blood insulin levels, and therefore may be used as a sugar substitute by people with type 2 diabetes. The glycemic index (GI) of erythritol is 0% of the GI for glucose and the insulin index (II) is 2% of the II for glucose.
=== Reproduction === In animals, relaxin widens the pubic bone and facilitates labor; it also softens the cervix (cervical ripening), and softens the pubic symphysis in rat and guinea pig models. Thus, for a long time, relaxin was looked at as a pregnancy hormone. However, its significance may reach much further. Relaxin may affect collagen metabolism, inhibiting collagen synthesis and enhancing its breakdown by increasing matrix metalloproteinases. It also enhances angiogenesis and is a potent renal vasodilator. In horses (Equus caballus), relaxin is also an important hormone involved in pregnancy; however, before pregnancy occurs, relaxin is expressed by ovarian structures during the oestrous cycle. Prior to ovulation, relaxin will be produced by ovarian stromal cells, which will promote secretion of gelatinases and tissue inhibitors of metalloproteinases. These enzymes will then aid the process of ovulation, which will lead to the release of a developed follicle into the fallopian tube. Furthermore, granular and theca cells in the follicles will express relaxin in increasing levels depending on their size. During early pregnancy, the preimplantation conceptus will express relaxin, which will promote angiogenesis in the endometrium by up-regulating VEGF. This will allow the endometrium to prepare for implantation. In horses alone, the embryo in the uterus will express relaxin mRNA at least 8 days after ovulation. Then as the conceptus develops expression will increase, which is likely to promote embryo development.
=== Sex and Gender === Jung believed in biologically based psychological differences between males and females. He articulated this view in his distinction between Eros or feminine psychology and Logos or masculine psychology. While he acknowledged that both Eros and Logos exist in males and females, in Jung's view Eros is more characteristic of female psychology and Logos of male psychology, and hence these categories retain 'statistical validity'. As Jung writes when reflecting on the genetic basis of these differences:
Sources: en.wikipedia.org
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.
No. Lyophilisation slows degradation rather than stopping it, and the rate depends on residual moisture, temperature and light exposure. Freezer storage extends useful life but does not make the material permanent.
A certificate is only as good as its traceability to a specific batch and a named laboratory. Documents lacking batch numbers, method descriptions or laboratory identifiers carry little weight. Confirming what was actually received generally requires a separate test of the material in hand.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.